| Identification | Back Directory | [Name]
4-Methyl-3-[[6-(methylamino)-4-pyrimidinyl]oxy]-N-[3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)phenyl]benzamide | [CAS]
1620820-12-3 | [Synonyms]
TL4-12
TL-4-12,TL412
4-Methyl-3-[[6-(methylamino)-4-pyrimidinyl]oxy]-N-[3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)phenyl]benzamide | [Molecular Formula]
C25H27F3N6O2 | [MDL Number]
MFCD31689241 | [MOL File]
1620820-12-3.mol | [Molecular Weight]
500.52 |
| Chemical Properties | Back Directory | [Boiling point ]
586.8±50.0 °C(Predicted) | [density ]
1.324±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.75±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TL4-12 is a selective MAP4K2/GCK inhibitor, dose-dependently downregulates IKZF1 and BCL-6 and leads to MM cell proliferation inhibition (IC50=37 nM) accompanied by induction of apoptosis. TL4-12 can be used to overcome immunomodulatory agent resistance in multiple myeloma (MM)[1]. | [storage]
Store at -20°C | [References]
[1] Shirong Li, et al. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma. Blood. 2021 Apr 1;137(13):1754-1764. DOI:10.1182/blood.2020006334 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|